Player is loading...
Wrap up of Panel Discussion 3
Raj Long , Bill and Melinda Gates Foundation, Vice-Chair, World Dementia Council
Tuesday, Dec. 12, 2017 · 3:23 p.m. · 04m 18s
Embed
Embed code is not allowed
This talk is part of a Private webcast, embeding is not permited.Transcriptions
Note: this content has been automatically generated.
00:00:00
thank you for the these are the times when i wish i had my own private jet and i
00:00:04
could could have just landed myself amongst all of you but that's not going to have so
00:00:09
that may say by what average discussion that was overall in the context of
00:00:13
the panelists and the questions in summary what we heard will is
00:00:19
and it ends of the observed differences we had uh it's
00:00:24
from different therapeutic areas from her again for maria and from valerie
00:00:29
as regulators without from option then to now uh in terms of way particularly i
00:00:35
think by the f. d. a. is and mash is really encouraging to hear
00:00:38
how the evolution of this topic f. d. a. is taken on and
00:00:43
the whole perspective is progressively getting to replace closer to where we can potentially be
00:00:49
able to answer some of the questions so i think that's very encouraging
00:00:53
and then also that but you know around maze advocacy uh engagement in europe
00:00:59
no matter which way we we no matter what we had in which uh we
00:01:02
we look at this i think at a very high level i would say
00:01:06
gender differences the perceived you observe differences does impact safety and efficacy
00:01:11
it's not exclusive to either one it does seem to impact well in the context
00:01:16
of what we heard from maybe marie and valerie if that is the case
00:01:20
and if we take into consideration the ask to close that gap on this one of the panelists
00:01:26
the real question we had was do we need to reconsider the way we test drops
00:01:32
testing doctors clinical research and companies particularly you were doing global research
00:01:38
do not do development for a single country they do across joe graphics
00:01:44
if that is the case the testing question for us is is
00:01:48
it good enough to to leave things as they are and
00:01:53
allows things to a ball bottom up or do we really want to take the bull by the whole in here
00:01:59
and do some uh much much bold uh and bigger thinking or
00:02:03
even destructive thinking and say what a if we actually
00:02:07
brought this topic up at a higher level in the context of i. c. h. o. i. c. h. just guidelines
00:02:14
fall many of the job of fees that are probably represented in that room
00:02:17
around how to approach a particular disease all safety in a consistent way
00:02:23
so what do we even take it up one level for the just
00:02:26
like we did with out simon i did mention alzheimer's last year
00:02:30
couple of years of hard work with the w. h. o. actually put it then into the global health assembly
00:02:37
is this a big enough problem for us to even consider taking the evidence
00:02:41
we have so far and integrating it into a white paper for example
00:02:47
and taking it for the as a proposal to any one of the
00:02:51
larger institutions like ice age will uh w. h. o. to
00:02:56
see what they consider putting this topic on the agenda because that's all we can do right now is on the agenda
00:03:03
and that's really play my thinking as the moderator listening to all of the conversations if
00:03:09
we leave it as it it's things will evolve maybe it could be ball
00:03:14
not sure but you will be bold in its own a pace it is not
00:03:18
a priority if we look at that's why we're here today discussing this
00:03:22
in the context of a global or universal clinical research but if there is evidence
00:03:27
here for us to feel comfortable enough shall we take a much oldest that's
00:03:33
really what i want to land as a moderate on this because that's that's why
00:03:38
i'm go wait in terms of thinking like we need to the mall
00:03:41
then just waiting for the steeple bottom up so many balls that that was just would pop
00:03:47
up everyone but as the moderator session i think i'd like to in that by saying
00:03:52
maybe a bit double the action do something tangible just to see how far will this
00:03:57
take this in the context of regulators research is an incentive rising patients to be
00:04:04
more engaged in input research that's it i think i've taken less than five minutes
Conference Program
Welcome Words
Maria Teresa Ferretti, President, Women's Brain Project
Dec. 12, 2017 · 8:48 a.m.
Welcome adress
Françoise Grossetête, member of the European Parliament
Dec. 12, 2017 · 8:55 a.m.
Presentation of the day
Sylvia Day, Forum host and WBP ambassador
Dec. 12, 2017 · 9:01 a.m.
Introduction of Elena Becker-Barroso
Elena Becker-Barroso, Editor-in-Chief of The Lancet Neurology
Dec. 12, 2017 · 9:21 a.m.
231 views
Introduction of Gillian Einstein
Gillian Einstein, University of Toronto, Canada
Dec. 12, 2017 · 9:28 a.m.
Introduction of Else Charlotte Sandset
Else Charlotte Sandset, Oslo University Hospital, Norway
Dec. 12, 2017 · 9:39 a.m.
Introduction of Carol Brayne
Carol Brayne, University of Cambridge, UK
Dec. 12, 2017 · 9:44 a.m.
Introduction of Maria Teresa Ferretti
Maria Teresa Ferretti, President, Women's Brain Project
Dec. 12, 2017 · 9:52 a.m.
158 views
Introduction of Liisa Galea
Liisa Galea, University of British Columbia, Canada
Dec. 12, 2017 · 9:56 a.m.
Introduction of Lawrence Rajendran
Lawrence Rajendran
Dec. 12, 2017 · 10:03 a.m.
245 views
Introduction of Thorsten Buch
Thorsten Buch, Director, Institute of Laboratory Animal Science (LTK), University of Zurich, Switzerland
Dec. 12, 2017 · 10:08 a.m.
Introduction of Meryl Comer
Meryl Comer , President & CEO, Geoffrey Beene Foundation Alzheimer's Initiative
Dec. 12, 2017 · 10:59 a.m.
Introduction of Mary Mittelman
Mary Mittelman, New York University School of Medicine, US
Dec. 12, 2017 · 11:05 a.m.
Introduction of Angela Abela
Angela Abela , University of Malta, Malta
Dec. 12, 2017 · 11:13 a.m.
Introduction of Tania Dussey-Cavassini
Tania Dussey-Cavassini, Former Swiss Ambassador for Global Health, Switzerland
Dec. 12, 2017 · 11:20 a.m.
480 views
Introduction of Rajendra Dhamane
Rajendra Dhamane
Dec. 12, 2017 · 11:29 a.m.
Introduction of Sofia Petersson
Dec. 12, 2017 · 1:23 p.m.
Introduction of Raj Long
Raj Long , Bill and Melinda Gates Foundation, Vice-Chair, World Dementia Council
Dec. 12, 2017 · 1:30 p.m.
201 views
Introduction of Antonella Santuccione Chadha
Antonella Santuccione Chadha , Swissmedic, Swiss Regulatory Agency, Switzerland
Dec. 12, 2017 · 1:32 p.m.
371 views
Introduction of Marsha B. Henderson
Marsha B. Henderson, Food and Drugs Administration, Office for Women's Health, US
Dec. 12, 2017 · 1:36 p.m.
Introduction of Maeve Cusack
Maeve Cusack, European Institute for Women's Health
Dec. 12, 2017 · 1:43 p.m.
Introduction of Hadine Joffe
Hadine Joffe, Harvard Medical School, US
Dec. 12, 2017 · 1:47 p.m.
Introduction of Maria Houtchens
Maria Houtchens, Harvard Medical School, US
Dec. 12, 2017 · 1:55 p.m.
Introduction of Valerie Bruemmer
Valerie Bruemmer, Senior Medical Advisor, Eli Lilly
Dec. 12, 2017 · 2:03 p.m.
Introduction of Malou Cristobal
Malou Cristobal, Polytrauma/ TBI / Vestibular Rehabilitation Program, New York Harbour
Dec. 12, 2017 · 2:08 p.m.
Panel Discussion: Sex and gender in clinical trials for brain and mental diseases – Reconsidering the way we test drugs
Dec. 12, 2017 · 2:12 p.m.
113 views
Wrap up of Panel Discussion 3
Raj Long , Bill and Melinda Gates Foundation, Vice-Chair, World Dementia Council
Dec. 12, 2017 · 3:23 p.m.
Presentation of Sofia, Robot
Sofia, Robot
Dec. 12, 2017 · 3:28 p.m.
Introduction of Nicoletta Iacobacci
Nicoletta Iacobacci , Singularity University Geneva
Dec. 12, 2017 · 3:32 p.m.
Introduction of Fabrizio Renzi
Fabrizio Renzi, Innovation and Technologies Director, IBM, Rome
Dec. 12, 2017 · 3:36 p.m.
Introduction of Joanna J. Bryson
Joanna J. Bryson , University of Bath, UK
Dec. 12, 2017 · 3:48 p.m.
Introduction of Myshkin Ingawale
Myshkin Ingawale, Facebook
Dec. 12, 2017 · 3:58 p.m.
Introduction of Kathryn Goetzke
Kathryn Goetzke, President, Chief Mood Officer & Founder, The Mood Factory, and Founder, iFred
Dec. 12, 2017 · 4:07 p.m.
Introduction of Nikolaos Mavridis
Nikolaos Mavridis , Interactive Robots and Media Labs, MIT, US
Dec. 12, 2017 · 4:13 p.m.
Panel discussion: Digital biomarkers and new technologies – New tools to support women's brain health
Dec. 12, 2017 · 4:26 p.m.
Closing remarks
Mara Hank Moret
Dec. 12, 2017 · 5:12 p.m.
605 views
